

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Barbara K. Finck et al.

Serial No.: 09/602,351

Filing Date: June 23, 2000

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR  
TREATMENT OF MEDICAL DISORDERS

Docket No.: 2943-A

Group Art Unit: 161

Examiner: to be assigned



RECEIVED  
JAN 30 2001  
TECH CENTER 1600/2900

#5  
A.9  
2/9/01

**BOX NON-FEE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

DEC 21 2000

**INFORMATION DISCLOSURE STATEMENT**

TECH CENTER 1600/2900

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. Many of the publications listed on the attached Form PTO-1449 were submitted previously in the parent application USSN 09/373.828, filed August 13, 1999. Applicants therefore are enclosing only copies of the documents not previously submitted, and listed below. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

1. 4,965,271 Mandrell et al.
2. 5,096,906 Mandrell et al.
3. 5,196,430 Mandrell et al.
4. 5,420,154 Christensen et al.
5. 5,508,300 Duplantier
6. 5,541,219 Fenton et al.
7. 5,596,013 Duplantier
8. 5,658,581 De Lacharriere et al.
9. 5,629,285 Black et al.
10. 5,691,382 Crimmin et al.
11. 5,700,838 Dickens et al.
12. 5,747,514 Beckett et al.
13. 5,756,449 Andersen et al.
14. 5,795,859 Rathjen et al.
15. 5,821,262 Crimmin et al.
16. 5,888,511 Skurkovich et al.
17. 5,958,413 Anagnostopulos et al.
18. 5,993,833 De Lacharriere et al.

RECEIVED


DEC 21 2000

TECH CENTER 1600/2900

19. 6,020,323 Cohen et al.
20. WO 95/06031
21. WO 95/35283
22. WO 95/35285
23. WO 96/00215
24. WO 96/01825
25. WO 98/17799
26. WO 98/24463
27. WO 98/46642
28. WO 99/15524
29. WO 99/18095
30. WO 99/31128
31. GB2291422A
32. EP 516785B1
33. EP 626 389A1
34. EP 639 079B1
35. EP 869 179 A1
36. EP 927 758A2
37. de Rie, M. A. et al.
38. Ettehadi, P., et al.
39. Höhler, T., et al.
40. Mease, P. et al.
41. Mease, P. et al.
42. Nickoloff, B.J.
43. Yazici, Y. et al.

Submission of these publications does not constitute an admission that any are "prior art" under 35 U.S.C. §102 or §103, and Applicants specifically reserve the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method. Applicants submit that the claims of the above-captioned application are directed to subject matter that is patentably distinct from the disclosures of the above-cited references.

Information Disclosure Statement  
USSN 09/602,351



RECEIVED  
JAN 30 2001  
2945-A  
TECH CENTER 1600/2900

To Applicants' knowledge, no office action on the merits has been mailed in the subject application. Thus, no fee is due for the filing of this information disclosure statement.

Respectfully submitted,

*Diana K. Sheiness*

Diana K. Sheiness  
Registration No. 35,356

RECEIVED

DEC 21 2000

TECH CENTER 1600/2900

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone (206) 587-0430

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX NON-FEE, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: Dec. 13, 2000

Signed *Nanci M. Kertson*  
Nanci M. Kertson